Q3 FY2026 · ended Sep 30, 2026 · Revenue $0, -100.0% YoY · Filed Nov 5, 2026
Scynexis Inc (SCYX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $0 and a net loss of $8.5 million. As of Sep 30, 2026 it held $47.2 million in cash and investments and $1.8 million in total debt.
Revenue
$0
-100.0% vs year-ago quarter
Net income
$-8.46M
+1.5% vs year-ago quarter
Operating cash flow
$-7.47M
+14.4% vs year-ago quarter
Free cash flow
—
EPS
$-0.71
+48.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
9.95M
-76.3% vs year-ago quarter
Net cash
$45.34M
Q3 FY2026
Operating margin
-126.9%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SCYX (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Jersey City, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1178253
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $235,000 | $0 | $18.6M | $334,000 |
| Operating income | -$9.8M | -$7.8M | -$16.9M | $10.5M | -$8.4M |
| Net income | -$8.5M | $7.4M | -$21.3M | $12.3M | -$8.6M |
| Diluted EPS | -$0.71 | $0.63 | -$0.42 | $0.07 | -$1.38 |
| Operating cash flow | -$7.5M | -$14.9M | -$8.1M | $18.4M | -$8.7M |
| Total assets | $68.0M | $75.0M | $77.6M | $59.0M | $51.1M |
| Total liabilities | $8.9M | $8.0M | $36.3M | $9.7M | $14.6M |
| Stockholders' equity | $59.0M | $66.9M | $41.3M | $49.4M | $36.4M |
| Cash and investments | $47.2M | $54.1M | $59.3M | $40.0M | $37.9M |
| Total debt | $1.8M | $1.9M | $2.1M | $2.2M | $2.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Sep 28, 2026 | Sep 25, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 22, 2026 | Sep 18, 2026 |
| 8-K |
Current report
Officer or director change, Other events
|
Sep 10, 2026 | Sep 9, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results, Other events
|
Jun 26, 2026 | Jun 25, 2026 |
All 744 Scynexis Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.